Cosmo Pharmaceuticals Announces Hiring of Investor Relations and Leadership Change Manager

Ad hoc announcement in accordance with art. 53 LR

Dublin, Ireland – December 30, 2021: Cosmo Pharmaceuticals NV (SIX: COPN) (“Cosmo”) announced today that Ms. Hazel Winchester has been appointed as Head of Investor Relations and will take up her duties on January 10, 2022.

Ms. Winchester brings nearly two decades of investor relations experience. She is a seasoned IR professional who previously held various positions for a Swiss Medtech and more recently for a biopharmaceutical company listed on SIX. Prior to that, Ms. Winchester worked with various companies in Toronto, Canada, including one that went from small to large cap listed on the Toronto Stock Exchange and NYSE. She served on the board of directors of the Canadian Institute for Investor Relations (CIRI) and recently joined the board of directors of IR Club Switzerland.

Alessandro Della Chà, CEO of Cosmo, commented: ‘We have been figuring out how to fulfill this important role for some time and now believe we have found the right fit in Hazel. I hope it will help us to strengthen the relationship with investors at this very important moment in Cosmo’s history.‘.

Cosmo further announced that Mr. Stefano Selva, current CSO, had resigned from Cosmo for personal reasons with effect from December 31, 2021. Given the structure and organization of the R&D department, the Company does not envisage a immediately fill the position.

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on the development and commercialization of products to treat certain gastrointestinal disorders and improve endoscopy quality measurements by facilitating the detection of colonic lesions. Cosmo develops and manufactures products that are distributed worldwide, including Lialda (R) and Uceris (R) / Cortiment (R). Cosmo has also developed medical devices for endoscopy and has partnered with Medtronic for the global distribution of GI Genius (TM), its artificial intelligence device, which uses artificial intelligence to help detect potential signs of Colon Cancer. Cosmo has licensed Aemcolo (R) to Red Hill Biopharma Ltd. for the US and licensed Relafalk (R) to Dr. Falk Gmbh for the EU and other countries. For more information about Cosmo and its products, please visit the Company’s website: www.cosmopharma.com